Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support
Explore new findings from the DanGer-SHOCK and ECLS-SHOCK trials, insights into high-risk percutaneous coronary intervention (PCI) in patients with reduced LVEF (left ventricular ejection fraction), and detailed subset analyses one year post-DanGer-SHOCK.
This #europcr 2025 session also highlights the latest evidence on Impella use in cardiogenic shock.
Don’t miss the chance to uncover key breakthroughs shaping the future of cardiogenic shock management—watch the full replay now!
Sponsored by Johnson & Johnson MedTech – Heart Recovery
More videos on PCRonline: https://www.pcronline.com/Cases-resou...
#mechanicalcirculatorysupport, #pci, #cardiogenicshock, #lvef, #coronaryinterventions